Somite AI Raises $47 Million in Series A Funding to Revolutionize Human Cell Therapy
Somite AI, an innovative TechBio company, has successfully closed its Series A funding round, raising more than $47 million to accelerate the development of human cell therapies. This funding will allow Somite AI to advance its proprietary AI platform, DeltaStem, which aims to revolutionize the way human cells are produced for therapeutic purposes.
The funding round was led by Khosla Ventures, with additional participation from prominent investors such as SciFi VC, the Chan Zuckerberg Initiative, Fusion Fund, Ajinomoto Group Ventures, Pitango HealthTech, and TechAviv. High-profile angel investors, including Dr. R. Martin Chavez, former Chairman of Recursion, and Fidji Simo, the outgoing CEO of Instacart and incoming CEO of Applications at OpenAI, also supported the round.
DeltaStem: A Game-Changer in Cell Therapy
At the heart of Somite AI’s mission is DeltaStem, a next-generation platform designed to accelerate the production of human cells for therapeutic use.
The DeltaStem foundation model is poised to revolutionize the development of various cell types, including beta cells for type 1 diabetes, articular cartilage for orthopedic applications, satellite cells for muscular diseases, and hematopoietic cells for blood disorders.
This groundbreaking technology significantly increases the efficiency of human cell production, providing a scalable, cost-effective solution to address complex health conditions.
Also read: Trump Announces $600 Billion US-Saudi Economic Deal, Focuses on AI, Defense, and Infrastructure
AI-Driven Efficiency in Cell Therapy
Somite AI’s proprietary capsule technology generates cell state transition data at an unprecedented scale, achieving 1000x greater efficiency compared to current methods. This data feeds directly into DeltaStem, enabling the company to rapidly develop cell differentiation protocols with unmatched purity, scalability, and reliability.
By generating the world’s largest cell signaling dataset, Somite AI aims to create AI-driven protocols that accelerate the production of various human cells, paving the way for a scalable solution for therapeutic applications.
Dr. Micha Breakstone, CEO of Somite AI, "We're building the foundation model for the human cell. By generating the world's largest cell signaling dataset at 1000x the efficiency of current methods, we're training DeltaStem to deliver protocols with unmatched purity, scalability, and reliability. We are rapidly driving towards an AlphaFold moment for developmental biology, enabling the scalable production of any cell, for anyone."
In traditional cell therapies, the production process is often expensive, slow, and unpredictable. However, Somite AI believes that AI can systematically address these challenges.
